Novartis launches Jakavi in 50+ countries; J&J to market hep C drug in Europe;

> Novartis ($NVS) has launched myelofibrosis drug Jakavi in Singapore and 50 other countries. Report

> Johnson & Johnson's ($JNJ) Janssen has won EU marketing authorization for hep C drug Olysio. Release

> Tolmar Pharma has regained marketing rights for prostate cancer drug Eligard in the U.S. and Puerto Rico. More

> A new report highlights the meningococcal vaccines market through 2019. Release

And Finally... Some tech companies are betting that sifting through patients' social media posts will yield critical side-effect insights that drugmakers will buy. More

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.